[Glutamate receptor antagonists as potential antiepileptic drugs].
Numerous antagonists of glutamate, belonging to N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists, were demonstrated to display anticonvulsant activity in various models of experimental epilepsy. Also, the glutamate antagonists enhanced the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. However, some combinations of conventional antiepileptics with NMDA receptor antagonists resulted in profound adverse effects. In contrast, the antagonists from the non-NMDA receptor group potentiated the anticonvulsant activity of conventional antiepileptics, with no side-effects being observed. In some cases, the combined treatments were superior to the antiepileptic drugs alone, as regards adverse effects. In no case, glutamate antagonists affected the plasma levels of antiepileptic drugs. These data seem to indicate that non-NMDA receptor antagonists bear more important clinical potential as adjuvant antiepileptic drugs.
Czuczwar
S J
SJ
Katedry i Zakładu Patofizjologii Akademii Medycznej w Lublinie. czuczwar@galen.imw.lublin.pl
D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism*; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D017470:Receptors, Glutamate / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects
D000927:Anticonvulsants; D017470:Receptors, Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid
Antagoniści kwasu glutaminowego jako potencjalne leki przeciwpadaczkowe.